JPLA
ADAP

Joseph P. Lucia & Associates’s Adaptimmune Therapeutics ADAP Stock Holding History

Joseph P. Lucia & Associates’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-375
Closed -$1K – 110
2022
Q2 		$1K Hold
375
– – ﹤0.01% 404
2022
Q1 		$1K Buy
+375
New +$1.01K ﹤0.01% 416

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Joseph P. Lucia & Associates's ADAP Position: Q3 2022 in Review

Joseph P. Lucia & Associates sold out of Adaptimmune Therapeutics (ADAP) in Q3 2022, closing a stake of 375 shares — an estimated $1K sold.

Joseph P. Lucia & Associates first reported a position in ADAP in Q1 2022 and held it in 2 quarters. The position peaked at $1K in Q2 2022. 68 funds tracked by Wall St. Rank hold ADAP as of Q3 2022.

  • Joseph P. Lucia & Associates reported no remaining Adaptimmune Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Joseph P. Lucia & Associates sold 375 Adaptimmune Therapeutics shares in Q3 2022, an estimated $1K.
  • Joseph P. Lucia & Associates first reported a position in Adaptimmune Therapeutics in Q1 2022 and held it in 2 quarters.
  • Joseph P. Lucia & Associates's Adaptimmune Therapeutics position peaked at $1K in Q2 2022.
  • 68 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2022.

Based on Joseph P. Lucia & Associates's 13F filing for Q3 2022, filed 28 Oct 2022.